Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tanezumab in Chronic Low Back Pain (TANGO)
NCT02528253Phase 3Completed
- Sponsor
- Pfizer
- Start
- Aug 2015
- Primary completion
- Oct 2017
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of tanezumab in chronic low back pain (CLBP) (5 arms), sponsored by Pfizer. Primary endpoint: Average Low Back Pain Intensity Score at 16 weeks. Started Aug 2015; status: completed.
02
Drugs
tanezumab
03
Conditions
chronic low back pain (CLBP)
Beyond the preview
Go deeper on NCT02528253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02528253.